1-6 of 6
Lei Feng, M.S.
Close
Sort by
Journal Articles

Peripheral Absolute Neutrophil, Mmonocyte and Lymphocyte Counts and Clinical Ooutcome in Diffuse Large B-Cell Lymphoma

Yiming Chen, MDPhD, Maria Alma Rodriguez, MD, Lei Feng, M.S., Weiqi Bi, MD, Liang Zhang, MD, PhD, Michael Wang
Journal: Blood
Blood (2014) 124 (21): 4416.
https://doi.org/10.1182/blood.V124.21.4416.4416
Published: 2014
Journal Articles

Phase 1 Study Of The Novel Kinesin Spindle Protein Inhibitor ARRY-520 + Carfilzomib (Car) In Patients With Relapsed and/Or Refractory Multiple Myeloma (RRMM)

Jatin J. Shah, M.D., Lei Feng, M.S., Sheeba K. Thomas, M.D., Donna M. Weber, M.D., Michael Wang, MD, Brandi Hilder, Raymond Alexanian, M.D., Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2013) 122 (21): 1982.
https://doi.org/10.1182/blood.V122.21.1982.1982
Published: 2013
Journal Articles

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

Felipe Samaniego, M.D., M.P.H, Jorge E Romaguera, MD, Nathan Fowler, MD, Michelle A. Fanale, MD, Jatin J. Shah, M.D., Peter McLaughlin, MD, Barbara Pro, MD, Vijairam Selvaraj, MD, Frank K Braun, PhD, Rohit Mathur, PhD, Lei Feng, M.S., Sattva Neelapu, MD, Larry W. Kwak, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3039.
https://doi.org/10.1182/blood.V122.21.3039.3039
Published: 2013
Journal Articles

Plasmablastic Lymphoma: 28 Patient Single Institution Experience

Krina Patel, MD, Lei Feng, M.S., Yasuhiro Oki, MD, Muzaffar Qazilbash, M.D., Tariq Muzzafar, MBBS, Donna M. Weber, M.D., Nathan Fowler, MD, Uday R Popat, MD, Sheeba K. Thomas, M.D., Michelle A. Fanale, MD, Yago Nieto, MD, PhD, Nina Shah, MD, Qaiser Bashir, MD, Fredrick B. Hagemeister, MD, Robert Z. Orlowski, M.D., Ph.D., Jatin J. Shah, M.D.
Journal: Blood
Blood (2013) 122 (21): 4310.
https://doi.org/10.1182/blood.V122.21.4310.4310
Published: 2013
Journal Articles

A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM)

Sheeba K. Thomas, M.D., Tamara M Haygood, M.D., Muzaffar H. Qazilbash, MD, A. Georgina Melendez, M.D., Roxana Galvis, Kay B Delasalle, B.S., Lei Feng, M.S., Tiffany A. Richards, M.S., Felipe Samaniego, M.D., M.P.H, Luhua Wang, M.D., Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D., Donna M. Weber, M.D.
Journal: Blood
Blood (2013) 122 (21): 4396.
https://doi.org/10.1182/blood.V122.21.4396.4396
Published: 2013
Journal Articles

Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups.

Sheeba K Thomas, M.D., Lei Feng, M.S., Kay B Delasalle, B.S., Michael Wang, M.D., Jatin J Shah, M.D., Robert Z Orlowski, M.D., Ph.D., Raymond Alexanian, M.D., Donna M Weber, M.D.
Journal: Blood
Blood (2009) 114 (22): 1668.
https://doi.org/10.1182/blood.V114.22.1668.1668
Published: 2009